Publications by authors named "Mickael Lothgren"

Claim this Profile
T
Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy.
Marc-Oliver Grimm, Emma Karim, Venediktos Kapetanakis, Mickael Lothgren, Alessia Ogareva

Oncol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proposal for a General Outcome-Based Value Attribution Framework for Combination Therapies.
Lotte Steuten, Mickael Lothgren, Andrew Bruce, Marco Campioni, Adrian Towse

Value Health· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why We Need a New Outcomes-Based Value Attribution Framework for Combination Regimens in Oncology.
Adrian Towse, Mickael Lothgren, Lotte Steuten, Andrew Bruce

Value Health· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
Joaquim Cristino, Jíndřich Finek, Petra Jandova, Martin Kolek, Bálint Pásztor, Mickael Lothgren

J Med Econ· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.
Gunilla Journath, Kristina Hambraeus, Emil Hagström, Billie Pettersson, Mickael Löthgren

BMC Cardiovasc Disord· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
Guillermo Villa, Mickael Lothgren, Lucie Kutikova, Peter Lindgren, Shravanthi R Gandra

Clin Ther· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
Shravanthi R Gandra, Guillermo Villa, Gregg C Fonarow, Mickael Lothgren, Peter Lindgren

Clin Cardiol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute and chronic impact of cardiovascular events on health state utilities.
Louis S Matza, Katie D Stewart, Shravanthi R Gandra, Philip R Delio, Brett E Fenster, Mickael Lothgren

BMC Health Serv Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain.
Josep Darbà, Lisette Kaskens, Francesc Sorio Vilela, Mickael Lothgren

Clinicoecon Outcomes Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland.
Mickael Lothgren, Erna Ribnicsek, Louise Schmidt, Wolfgang Habacher, Jonas Lundkvist

Eur J Hosp Pharm· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection.
Christian Asseburg, Michael Willis, Mickael Löthgren, Niko Seppälä, Mika Hakala

Schizophr Res Treatment· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.
A Brett Hauber, Jochen Fleischmann, Mickael Lothgren, Michele Wilson, Annette Lam

J Opioid Manag· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
Ola Ghatnekar, Catharina Hjortsberg, Magnus Gisslén, Stefan Lindbäck, Mickael Löthgren

Pharmacoeconomics· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
Karen Moeremans, Lieven Annemans, Mickael Löthgren, Gabriele Allegri, Veronique Wyffels

Pharmacoeconomics· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
Andrew M Hill, Kelly Gebo, Lindsay Hemmett, Mickael Löthgren, Gabriele Allegri

Pharmacoeconomics· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden.
Michael Willis, Marianne Svensson, Mickael Löthgren, Bo Eriksson, Anders Berntsson

Eur J Health Econ· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness of long-acting risperidone in Sweden.
Marja Hensen, Bart Heeg, Mickael Löthgren, Ben van Hout

Appl Health Econ Health Policy· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacoeconomic analysis of compliance gains on antipsychotic medications.
Joep Damen, Per-Olof Thuresson, Bart Heeg, Mickael Lothgren

Appl Health Econ Health Policy· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain.
Sibilia Quilici, Jeremy Chancellor, Mickael Löthgren, Dominique Simon, Gérard Said

BMC Neurol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ola Ghatnekar, Thor Alvegård, Nils Conradi, Stig Lenhoff, Ulf-Henrik Mellqvist

Clin Ther· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do we fully understand the economic value of vaccines?
Michael Drummond, Catherine Chevat, Mickael Lothgren

Vaccine· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evidence in affective disorders: a review.
Mickael Löthgren

Eur J Health Econ· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evidence in anxiety disorders: a review.
Mickael Löthgren

Eur J Health Econ· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evidence in psychotic disorders: a review.
Mickael Löthgren

Eur J Health Econ· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical industry's perspective on health technology assessment.
Mickael Lothgren, Mark Ratcliffe

Int J Technol Assess Health Care· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis